The Real World Evidence Solutions Market is Set to Explode to $12.44 Billion by 2031
According to a recent report by MarketsandMarkets™, the Real World Evidence (RWE) Solutions Market is projected to surge to USD 12.44 billion by the year 2031. This represents a tremendous growth from its current valuation of USD 6.22 billion, making the projected compound annual growth rate (CAGR) 14.9% during the forecast period from 2026 to 2031.
In 2025, North America was the dominant player, holding approximately 58.3% of the real-world evidence solutions market share. The market is segmented mainly into two components: services and data sets, with the latter expected to witness the fastest growth rate at a remarkable 15.5% during the forecast period. This growth is primarily attributed to the extensive generation of real-world data (RWD) from electronic health records (EHRs), pharmaceutical claims, patient registries, and other innovative digital health technologies.
A significant shift from volume-based care to more value-based care models has catalyzed investment in research and development for both pharmaceuticals and medical devices. For instance, an increase in submissions for new drug applications (NDA) and biologics license applications (BLA) that contain RWE has been noted—quadrupling between FY2023 and FY2025. The FDA has begun relying on RWE to inform decisions for several critical treatments, including Onapgo, Isturisa, and Gamifant.
Recent advancements in technology are pushing the envelope in the RWE space. AI-driven solutions are becoming the backbone for evidence generation, enabling developers to leverage comprehensive data analytics in a privacy-preserving environment. A prime example can be seen with HealthVerity, which launched eXOs in September 2025—a service that utilizes an AI-enabled platform allowing biopharma companies to extract insights from real-world data through natural-language queries.
In terms of application segments, drug development and approvals have been shown to command the largest market share at 32.0% in 2025. Specifically, cardiovascular diseases appeared as the primary focus area due to their high prevalence and the immense need for long-term studies that ascertain treatment effectiveness. This segment is rapidly expanding, aided by the proliferation of EHRs and patient-generated data, which broaden the scope of evidence generation.
Medtech firms are leading in terms of market growth, as these companies increasingly depend on RWE to substantiate the safety and performance efficacy of their products. Additionally, the connectivity of devices and remote monitoring solutions is facilitating a promising outlook for more detailed evidence generation in this segment.
Geographically, North America is expected to continue its reign in the RWE market, buoyed by a supportive regulatory environment and an expansive healthcare data landscape. The US tracks significant numbers in RWD networks, covering over 318 million lives, thereby offering a wealth of data that is pivotal for stakeholders.
The competitive landscape boasts several key players who are actively consolidating their positions in the market. Companies such as IQVIA, Merative, and Oracle are consistently at the forefront, primarily due to their expansive RWD/RWE platforms and the ability to integrate advanced analytics within regulatory frameworks.
Conclusion
With the RWE Solutions Market anticipating a robust CAGR until 2031, the landscape is evolving rapidly. The increasing importance of data-driven evidence is transforming the healthcare field, ushering in a new era where advanced analytics and AI capabilities can enrich decision-making processes. This growth trajectory paints a bright future for stakeholders operating within this space, as they move to harness the unprecedented opportunities presented by real-world data.
Market Overview
In 2025, North America was the dominant player, holding approximately 58.3% of the real-world evidence solutions market share. The market is segmented mainly into two components: services and data sets, with the latter expected to witness the fastest growth rate at a remarkable 15.5% during the forecast period. This growth is primarily attributed to the extensive generation of real-world data (RWD) from electronic health records (EHRs), pharmaceutical claims, patient registries, and other innovative digital health technologies.
Key Market Drivers
A significant shift from volume-based care to more value-based care models has catalyzed investment in research and development for both pharmaceuticals and medical devices. For instance, an increase in submissions for new drug applications (NDA) and biologics license applications (BLA) that contain RWE has been noted—quadrupling between FY2023 and FY2025. The FDA has begun relying on RWE to inform decisions for several critical treatments, including Onapgo, Isturisa, and Gamifant.
Technological Advancements
Recent advancements in technology are pushing the envelope in the RWE space. AI-driven solutions are becoming the backbone for evidence generation, enabling developers to leverage comprehensive data analytics in a privacy-preserving environment. A prime example can be seen with HealthVerity, which launched eXOs in September 2025—a service that utilizes an AI-enabled platform allowing biopharma companies to extract insights from real-world data through natural-language queries.
Key Applications
In terms of application segments, drug development and approvals have been shown to command the largest market share at 32.0% in 2025. Specifically, cardiovascular diseases appeared as the primary focus area due to their high prevalence and the immense need for long-term studies that ascertain treatment effectiveness. This segment is rapidly expanding, aided by the proliferation of EHRs and patient-generated data, which broaden the scope of evidence generation.
Rising End-User Segments
Medtech firms are leading in terms of market growth, as these companies increasingly depend on RWE to substantiate the safety and performance efficacy of their products. Additionally, the connectivity of devices and remote monitoring solutions is facilitating a promising outlook for more detailed evidence generation in this segment.
Regional Insights
Geographically, North America is expected to continue its reign in the RWE market, buoyed by a supportive regulatory environment and an expansive healthcare data landscape. The US tracks significant numbers in RWD networks, covering over 318 million lives, thereby offering a wealth of data that is pivotal for stakeholders.
Competitive Landscape
The competitive landscape boasts several key players who are actively consolidating their positions in the market. Companies such as IQVIA, Merative, and Oracle are consistently at the forefront, primarily due to their expansive RWD/RWE platforms and the ability to integrate advanced analytics within regulatory frameworks.
Conclusion
With the RWE Solutions Market anticipating a robust CAGR until 2031, the landscape is evolving rapidly. The increasing importance of data-driven evidence is transforming the healthcare field, ushering in a new era where advanced analytics and AI capabilities can enrich decision-making processes. This growth trajectory paints a bright future for stakeholders operating within this space, as they move to harness the unprecedented opportunities presented by real-world data.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.